Analyst Price Target is $107.86
▲ +32.85% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $107.86, with a high forecast of $125.00 and a low forecast of $89.00. The average price target represents a 32.85% upside from the last price of $81.19.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Bio-Techne. This Buy consensus rating has held steady for over two years.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T